GO
Loading...

India

More

  • Shares of the company, whose customers include AT&T Inc and Verizon Communications Inc, rose about 3 percent in extended trading. AT&T has estimated capital expenditure of about $21 billion for this year, while Verizon has said it expected to spend about $17 billion.

  • April 23- LPL Financial Holdings Inc, one of the five biggest U.S. broker-dealers, reported a 3 percent fall in quarterly profit as operating expenses ballooned to almost $1 billion. The company's net income slipped to $53.1 million in the first quarter ended March 31 from $54.7 million. On a per share basis, earnings were flat at 51 cents.

  • April 23- Xilinx Inc, a maker of programmable chips, forecast current-quarter revenue largely below analysts' estimates, sending the company's shares down 6 percent in extended trading. Xilinx said it expected first-quarter revenue to stay flat to rise 4 percent from the fourth quarter.

  • April 23- Videoconferencing equipment maker Polycom Inc reported a better-than-expected quarterly adjusted profit as cost cuts, including workforce reductions, boosted margins. The company posted a first-quarter loss of $4 million, or 3 cents per share, compared with a profit of $2.6 million, or 1 cent per share, a year earlier.

  • Texas Instruments' quarterly revenue rises Wednesday, 23 Apr 2014 | 4:40 PM ET

    April 23- Texas Instruments Inc reported a 3 percent rise in quarterly revenue due to improved demand for its chips used in cars, appliances, computers and industrial products and strong growth in its analog chips business.

  • Angie's List posts smaller quarterly loss Wednesday, 23 Apr 2014 | 4:25 PM ET

    April 23- Angie's List Inc, which operates a website that allows users to review local businesses, reported a smaller quarterly loss as it signed up more paid customers for its services. The company's net loss narrowed to $3.8 million, or 6 cents per share, in the quarter ended March 31 from $7.9 million, or 14 cents per share, a year earlier.

  • F5 Networks' quarterly revenue rises 20 pct Wednesday, 23 Apr 2014 | 4:13 PM ET

    April 23- Network equipment maker F5 Networks Inc reported a 20 percent rise in quarterly revenue due to higher demand for its software-defined application services and security software. The company's net income rose to $69.6 million, or 91 cents per share, in the second quarter ended March 31 from $63.4 million, or 80 cents per share, a year earlier.

  • April 23- Discount brokerage E* Trade Financial Corp's quarterly profit more than doubled, helped by a drop in provision for loan losses and a surge in trading activity. The company's net income rose to $97 million, or 33 cents per share, in the first quarter ended March 31, from $35 million, or 12 cents per share, a year earlier.

  • GE names new lead independent director Wednesday, 23 Apr 2014 | 3:07 PM ET

    April 23- General Electric Co named John Brennan as its lead independent director, succeeding Ralph Larsen, who retires on Wednesday. Brennan will also be the chairman of GE's management development and compensation committee, the company said in a filing with the U.S. Securities and Exchange Commission.

  • Sony to enter real estate business- Nikkei Wednesday, 23 Apr 2014 | 2:32 PM ET

    April 24- Sony Corp will branch out into the real-estate business in August and plans to take the unit public in three years, the Nikkei reported without citing a source. Sony recently set up a real-estate unit in Tokyo, with the aim of generating annual sales of 50 billion yen in five years, the newspaper said.

  • *First-qtr earnings per share $0.79 vs est. April 23- Dow Chemical Co said it expected margins to grow in almost all of its businesses in the near term, after tight cost control helped it lift margins in the first quarter.

  • April 23- Spectrum Pharmaceuticals Inc said it expects to seek U.S. marketing approval for its blood cancer drug in the third quarter, after the treatment was shown to be safe and effective in a key mid-stage trial. Roth Capital Partners analyst Joseph Pantginis said he expects CE-Melphalan to receive full approval next year.

  • April 23- Dow Chemical Co, the No. 1 U.S. chemical maker by sales, reported a stronger-than-expected rise in quarterly profit as cost controls helped to boost margins in its divisions that make coatings, plastics and crop-protection products. Dow Chemical cut 5 percent of its workforce and shuttered 20 plants in late 2012..

  • April 23- Ingersoll-Rand Plc, best known for its Trane airconditioners, forecast current-quarter earnings above estimates after reporting better-than-expected first-quarter results, helped by higher sales of its heating and cooling systems.

  • April 23- Johnson Controls Inc reported a better-than-expected quarterly profit as higher vehicle production in key markets drove up sales of car seats and other auto parts. Johnson Controls cut its 2014 earnings forecast to adjust for the sale of the electronics business.

  • April 23- Manpower Group Inc's quarterly profit almost tripled, helped by a recovery in hiring in Europe and lower costs, and it forecast accelerating growth in the current quarter.

  • April 23- Spectrum Pharmaceuticals Inc said its experimental blood cancer drug was shown to be safe and effective in a mid-stage trial, sending its shares up 10 percent. Spectrum Pharmaceuticals acquired development and marketing rights to the drug from Ligand Pharmaceuticals Inc in March 2013.

  • April 23- Dow Chemical Co, the No. 1 U.S. chemical maker by sales, reported a better-than-expected rise in quarterly profit as cost controls helped to boost margins in businesses that make coatings, plastics and crop-protection products.

  • April 23- Manpower Group Inc's quarterly profit almost tripled, helped partly by improved hiring in Europe and lower selling and administrative costs. The world's third-largest staffing company said its net income rose to $70.1 million, or 86 cents per share, in the first quarter ended March 31, from $23.9 million, or 31 cents per share, a year earlier.

  • Spectrum Pharma's cancer drug meets main goal in trial Wednesday, 23 Apr 2014 | 7:26 AM ET

    April 23- Spectrum Pharmaceuticals said its experimental cancer drug was shown to be safe and effective in a mid-stage trial. Spectrum's drug, Captisol-enabled melphalan, is an intravenous formulation of a common chemotherapy drug melphalan, and is being tested in multiple myeloma patients undergoing stem cell transplants.